Clinical Study
Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy
Table 3
Study and normative population data for incidences of adverse events during pregnancy.
| Adverse event | UK | South Africa | Study | Population | Study | Population |
| Perinatal mortality | 0 | 8/1000 | 45/1000 | 32.5/1000 | Maternal mortality | 0 | 12.2/100000 | 0 | 11/100000 | Hypertensive disease | 9% | 10% | 8% | 10% | Eclampsia | 0 | 1/2000 | 0 | 1/1300 | Antepartum haemorrhage | 3.8% | 2–5% | 3.4% | 2–5% | Abruptio placenta | 0 | 0.5–1.8% | 2.2% | 0.6% | Preterm labour | 3.8% | 5.1% | 5.6% | 11% | Caesarean section rate | 26% | 22% | 35% | 12% | Assisted vaginal deliveries | 23% | 10.5% | 8% | 5% |
|
|
References from internal report by S. W. Lindow [10–21].
|